^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    albumin-bound paclitaxel

    i
    Other names: ABI007, ABI-007, SNA-001, HC007
    Company:
    Generic mfg.
    Drug class:
    Tubulin inhibitor
    Related drugs:
    1d
    The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=25, Recruiting, Hebei Medical University Fourth Hospital
    New P2 trial
    |
    cisplatin • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    1d
    A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies (clinicaltrials.gov)
    P1/2, N=252, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • gemcitabine • albumin-bound paclitaxel
    2d
    Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis (clinicaltrials.gov)
    P2, N=40, Recruiting, Mayo Clinic | Trial completion date: May 2027 --> Jul 2029 | Trial primary completion date: May 2026 --> Jul 2029
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    cisplatin • albumin-bound paclitaxel • mitomycin
    2d
    Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer (clinicaltrials.gov)
    P2, N=23, Completed, Emory University | Active, not recruiting --> Completed
    Trial completion
    |
    gemcitabine • albumin-bound paclitaxel • Xermelo (telotristat etiprate)
    2d
    BRICES: QL1706 Plus Chemotherapy for Borderline Resectable Esophageal Cancer (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    cisplatin • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    2d
    QL1706 Plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A Phase II Trial (clinicaltrials.gov)
    P2, N=50, Recruiting, Affiliated Cancer Hospital & Institute of Guangzhou Medical University
    New P2 trial
    |
    cisplatin • carboplatin • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    2d
    A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    gemcitabine • albumin-bound paclitaxel • oxaliplatin • irinotecan • BMS‐986504
    2d
    Phase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplatin (TP) Via Hepatic Arterial Infusion for Advanced Breast Cancer Patients With Liver Metastases After Failure of Standard Therapy (clinicaltrials.gov)
    P2, N=30, Recruiting, Zhejiang Cancer Hospital
    New P2 trial
    |
    albumin-bound paclitaxel • Aqupla (nedaplatin)
    2d
    High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=29, Not yet recruiting, Emory University | Trial completion date: Feb 2027 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel
    3d
    A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer (clinicaltrials.gov)
    P1/2, N=220, Not yet recruiting, Nanjing Leads Biolabs Co.,Ltd
    New P1/2 trial
    |
    Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel
    3d
    A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation (clinicaltrials.gov)
    P1/2, N=440, Recruiting, Tyligand Pharmaceuticals (Suzhou) Limited | N=150 --> 440
    Enrollment change
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    Erbitux (cetuximab) • paclitaxel • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium
    3d
    BGB-LC-201: A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=400, Active, not recruiting, BeiGene | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed • BGB-15025 • BGB-A445 • alcestobart (LBL-007)